<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02973594</url>
  </required_header>
  <id_info>
    <org_study_id>16-1363</org_study_id>
    <nct_id>NCT02973594</nct_id>
  </id_info>
  <brief_title>Pulse Reduction On Beta-blocker and Ivabradine Therapy</brief_title>
  <acronym>PROBE-IT</acronym>
  <official_title>Pulse Reduction On Beta-blocker and Ivabradine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure with reduced left ventricular ejection fraction (HFrEF) is the most common form&#xD;
      of chronic heart failure in subjects ≤ 75 years of age. Beta-blocker therapy greatly reduces&#xD;
      mortality and improves ventricular function in HFrEF patients, but 30-40% of patients do not&#xD;
      show improvement in ventricular function with beta blockade.&#xD;
&#xD;
      An extensive gene signaling network downstream from the beta1-adrenergic receptor, the&#xD;
      primary target of beta-blocker therapy is likely important for development and progression&#xD;
      HFrEF. Pathologic changes in this gene signaling network are only reversed towards normal&#xD;
      levels when ventricular function improves. One potential mechanism for failure to improve&#xD;
      ventricular function in HFrEF patients unresponsive to beta blocker therapy is a lack of&#xD;
      heart rate reduction.&#xD;
&#xD;
      Ivabradine is an FDA-approved medication believed to have therapeutic benefit in HFrEF&#xD;
      patients through reduction in heart rate independent of beta-blockade. Ivabradine has been&#xD;
      shown to reduce the risk of hospitalization for worsening HF in patients with stable,&#xD;
      symptomatic chronic heart failure with reduced EF (≤ 35%)in sinus rhythm with resting heart&#xD;
      rate ≥ 70 bpm and who are on maximally tolerated doses of beta blockers or who have a&#xD;
      contraindication to beta blockers.&#xD;
&#xD;
      Given the high rate of mortality and hospitalization of HFrEF patients even with current&#xD;
      therapies, there is a large unmet need for improving HFrEF therapy. The goals of this study&#xD;
      are to test the hypothesis that heart rate reduction is an important antecedent for&#xD;
      improvement in ventricular function, and to identify components of the beta1-adrenergic&#xD;
      receptor gene signaling network responsible for improvement in ventricular function caused by&#xD;
      heart rate reduction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Pulse Reduction on Beta-blocker and Ivabradine Therapy (PROBE-IT) Study is a&#xD;
      double-blind, randomized, two-arm parallel group, placebo-controlled design that compares the&#xD;
      effect of heart rate reduction on ventricular reverse remodeling (assessed by LVEF change at&#xD;
      24 weeks) and on the beta1-gene signaling network in NYHA Class I-III HFrEF patients with an&#xD;
      idiopathic dilated cardiomyopathy etiology (HFrEF/IDC), who are in sinus rhythm and whose&#xD;
      heart rates remain ≥ 70 bpm on target or maximally tolerated doses of beta-blockers to which&#xD;
      they have evidence of non-response by LVEF (&lt; 5 absolute percentage points).&#xD;
&#xD;
      Eligible patients will be randomized (2:1) to blinded treatment with ivabradine or matching&#xD;
      placebo and will be initiated as per Corlanor® prescribing information over 4 weeks. The dose&#xD;
      at 4 weeks post randomization will be considered the intention-to-treat end of titration&#xD;
      dose, but further dose adjustment can be made based on clinical factors.&#xD;
&#xD;
      The primary endpoint, i.e., effect of heart rate reduction on reverse remodeling (LVEF), will&#xD;
      be assessed after 24 weeks. LV phenotyping by 3D-echocardiography, endomyocardial biopsy and&#xD;
      coronary sinus sampling for cardiac norepinephrine levels will be performed at baseline and&#xD;
      at 24 weeks. Exercise testing at baseline will be performed to assess level of beta blockade.&#xD;
      Upon completion of the study, gene expression in endomyocardial biopsy tissue samples for&#xD;
      each patient will be quantified using RNA-seq and quantified with respect to phenotypic&#xD;
      measurements including LVEF and heart rate changes.&#xD;
&#xD;
      After the Week 24 Visit, patients will return for an End-of-Study Visit and be offered open&#xD;
      label ivabradine with dose initiation accomplished by stopping study drug and starting&#xD;
      Corlanor at 5 mg BID or 2.5 mg BID if the patient is taking that dose of study drug.&#xD;
      Investigators and patients will not be informed of the blinded study drug assignment at the&#xD;
      time of study completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular reverse remodeling according to heart rate response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Improvement in left ventricular ejection fraction (LVEF) of ≥ 5 absolute percentage points in patients above vs. below median HR reduction for all subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of gene expression abundances by heart rate response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Quantification of changes in mRNA and microRNA abundance based on response above and below median for all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular reverse remodeling by treatment group (ivabradine vs. placebo)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Comparison of change (absolute LVEF percentage points) in subjects randomized to ivabradine vs. placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Dilated Cardiomyopathies, Idiopathic</condition>
  <condition>Heart Failure, Systolic</condition>
  <condition>Ventricular Remodeling</condition>
  <condition>Electrical Remodeling</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive ivabradine 2.5-7.5 mg PO bid in addition to baseline maximum-tolerated beta-blocker therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo bid in addition to baseline maximum-tolerated beta-blocker therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <arm_group_label>Ivabradine</arm_group_label>
    <other_name>Corlanor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. History of non-ischemic (confirmed by coronary angiogram), non-valvular dilated&#xD;
             cardiomyopathy considered to be idiopathic, HFrEF NYHA Class I, II, or III.&#xD;
&#xD;
          3. Must have experienced a sign or symptom of clinical heart failure at some time within&#xD;
             the preceding 12 months.&#xD;
&#xD;
          4. In sinus rhythm at Screening Visit.&#xD;
&#xD;
          5. Resting HR ≥ 70 bpm at the Screening Visit.&#xD;
&#xD;
          6. Receiving guideline-indicated oral renin-angiotensin-adosterone system (RAAS)&#xD;
             inhibitor therapy at the Randomization Visit, i.e., an ACE inhibitor, angiotensin&#xD;
             receptor blocker, or sacubitril/valsartan plus a mineralocorticoid receptor antagonist&#xD;
             as tolerated.&#xD;
&#xD;
          7. May have ICD or CRT device as indicated.&#xD;
&#xD;
          8. Receiving beta-blocker therapy for ≥ 6 months and target doses for ≥ 3 months prior to&#xD;
             Baseline Visit.&#xD;
&#xD;
             Target dose of carvedilol is 25 mg BID, and metoprolol succinate, 150 mg/day. Patients&#xD;
             who are not receiving doses that are at least at these target levels will have their&#xD;
             heart failure beta-blocker up-titrated to target and an LVEF re-measured in 3 months,&#xD;
             at which time they could be eligible for enrollment. Patients on &lt; target doses who&#xD;
             are intolerant to higher than target doses may be enrolled.&#xD;
&#xD;
          9. Evidence of stable or declining LVEF, defined as no increase by ≥ 5 % on a measurement&#xD;
             done within 6 months of screening compared to the most recent historical measurement&#xD;
             performed within 36 months of the index measure. Must have been on a dose of ≥ 50% of&#xD;
             target during the period that documented the lack of a reverse remodeling response.&#xD;
             Prior LVEF measurements could have been performed by any imaging technique, e.g.,&#xD;
             echocardiography, radionuclide methods, MRI, or contrast ventriculography.&#xD;
&#xD;
         10. Women of childbearing potential must have a negative serum pregnancy test at the&#xD;
             Screening Visit and a negative urine pregnancy test at the Baseline and Randomization&#xD;
             Visits.&#xD;
&#xD;
             a. Women who are surgically sterile or post-menopausal for at least 12 months are not&#xD;
             considered to be of childbearing potential.&#xD;
&#xD;
         11. Women of childbearing potential must agree to use a highly effective contraception for&#xD;
             the duration of the trial and for at least 30 days following the last dose of study&#xD;
             drug.&#xD;
&#xD;
         12. Must be competent to understand the information given in the Institutional Review&#xD;
             Board (IRB) informed consent form (ICF).&#xD;
&#xD;
         13. Echocardiographic parasternal window adequate for measuring LV volumes by 3D-echo.&#xD;
&#xD;
         14. Must sign the ICF prior to the initiation of any study procedure and not withdraw&#xD;
             consent prior to the Randomization Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. NYHA Class IV symptoms at the Randomization Visit.&#xD;
&#xD;
          2. History of HF due to or associated with uncorrected primary valvular disease or&#xD;
             history of ischemic heart disease.&#xD;
&#xD;
          3. Any history of atrial fibrillation (even if in sinus rhythm at present).&#xD;
&#xD;
          4. Systolic blood pressure &lt; 90/50 mmHg at the Screening Visit.&#xD;
&#xD;
          5. Significant fluid overload at the Randomization Visit, in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
             Evidence of significant fluid overload may include:&#xD;
&#xD;
               1. Mean jugular venous pressure above the clavicle at 90°.&#xD;
&#xD;
               2. Liver congestion.&#xD;
&#xD;
               3. Moist pulmonary rales post-cough.&#xD;
&#xD;
               4. Peripheral edema beyond 1+ pedal not explained by local factors.&#xD;
&#xD;
          6. History of untreated symptomatic bradycardia or if symptomatic bradycardia is likely&#xD;
             on full dose of study drug in the opinion of the Investigator.&#xD;
&#xD;
          7. Moderate to severe asthma or other obstructive lung disease requiring chronic use (&gt; 2&#xD;
             days/week) of an inhaled β2-selective adrenergic agonist &lt; 7 days of the Randomization&#xD;
             Visit.&#xD;
&#xD;
          8. Untreated thyroid disease, in the opinion of the Investigator, at the Randomization&#xD;
             Visit.&#xD;
&#xD;
          9. Serum potassium &lt; 3.5 mmol/L at the Screening Visit.&#xD;
&#xD;
             a. Lab value will be assessed by the central lab at the Screening Visit and any&#xD;
             exclusionary results must be corrected prior to randomization as documented by either&#xD;
             the central or local lab.&#xD;
&#xD;
         10. Renal failure requiring dialysis, serum creatinine &gt; 2.5 mg/dL, or an estimated&#xD;
             creatinine clearance &lt; 30 mL/min (Cockcroft-Gault) at the Screening Visit.&#xD;
&#xD;
             a. Lab values will be assessed by the central lab at the Screening Visit and any&#xD;
             exclusionary results must be corrected prior to randomization as documented by either&#xD;
             the central or local lab.&#xD;
&#xD;
         11. Significant intrinsic liver disease or a total bilirubin &gt; 2.5 mg/dL at the Screening&#xD;
             Visit.&#xD;
&#xD;
             a. Lab value will be assessed by the central lab at the Screening Visit and any&#xD;
             exclusionary results must be corrected prior to randomization as documented by either&#xD;
             the central or local lab.&#xD;
&#xD;
         12. Participation in a clinical study or treatment with an investigational drug or device&#xD;
             within 30 days of the Screening Visit (or 5 half-lives of the investigational agent,&#xD;
             whichever is longer).&#xD;
&#xD;
         13. Comorbid condition or illness which, in the opinion of the Investigator, may limit&#xD;
             life expectancy to less than 5 years.&#xD;
&#xD;
         14. Serious or active medical or psychiatric condition which, in the opinion of the&#xD;
             Investigator, may interfere with treatment, assessment, or compliance with the&#xD;
             protocol.&#xD;
&#xD;
         15. History of alcohol, drug, or chemical abuse that, in the opinion of the Investigator,&#xD;
             could impair or limit the patient's full participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R Bristow, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kao DP, Lowes BD, Gilbert EM, Minobe W, Epperson LE, Meyer LK, Ferguson DA, Volkman AK, Zolty R, Borg CD, Quaife RA, Bristow MR. Therapeutic Molecular Phenotype of beta-Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy. Circ Cardiovasc Genet. 2015 Apr;8(2):270-83. doi: 10.1161/CIRCGENETICS.114.000767. Epub 2015 Jan 30.</citation>
    <PMID>25637602</PMID>
  </reference>
  <reference>
    <citation>Lowes BD, Zolty R, Minobe WA, Robertson AD, Leach S, Hunter L, Bristow MR. Serial gene expression profiling in the intact human heart. J Heart Lung Transplant. 2006 May;25(5):579-88. doi: 10.1016/j.healun.2006.01.006. Epub 2006 Apr 11.</citation>
    <PMID>16678038</PMID>
  </reference>
  <reference>
    <citation>Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002 May 2;346(18):1357-65. doi: 10.1056/NEJMoa012630.</citation>
    <PMID>11986409</PMID>
  </reference>
  <reference>
    <citation>Tardif JC, O'Meara E, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K; SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011 Oct;32(20):2507-15. doi: 10.1093/eurheartj/ehr311. Epub 2011 Aug 29.</citation>
    <PMID>21875858</PMID>
  </reference>
  <reference>
    <citation>Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010 Sep 11;376(9744):886-94. doi: 10.1016/S0140-6736(10)61259-7.</citation>
    <PMID>20801495</PMID>
  </reference>
  <reference>
    <citation>Bristow MR. Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011 Oct 28;109(10):1176-94. doi: 10.1161/CIRCRESAHA.111.245092.</citation>
    <PMID>22034480</PMID>
  </reference>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2016</study_first_posted>
  <last_update_submitted>October 31, 2022</last_update_submitted>
  <last_update_submitted_qc>October 31, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>left ventricular reverse remodeling</keyword>
  <keyword>beta-1 adrenergic receptor signaling</keyword>
  <keyword>idiopathic dilated cardiomyopathy</keyword>
  <keyword>HCN4 inhibition</keyword>
  <keyword>beta-1 adrenergic receptor blocker</keyword>
  <keyword>gene expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
    <mesh_term>Atrial Remodeling</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon completion of primary data analysis, all gene expression data will be submitted to the Gene Expression Omnibus (GEO). In addition to the standard descriptive and protocol information, the Metadata Spreadsheet will contain subject information required to reproduce primary analyses. Once released by GEO these data will be available for public download. The investigators anticipate this to be complete approximately 2 years after the completion of final subject follow-up.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02973594
org study id: 16-1363
nct id: NCT02973594
lead sponsor: 
collaborator: 
collaborator: 
has dmc: Yes
Heart failure with reduced left ventricular ejection fraction (HFrEF) is the most common form
      of chronic heart failure in subjects ≤ 75 years of age. Beta-blocker therapy greatly reduces
      mortality and improves ventricular function in HFrEF patients, but 30-40% of patients do not
      show improvement in ventricular function with beta blockade.

      An extensive gene signaling network downstream from the beta1-adrenergic receptor, the
      primary target of beta-blocker therapy is likely important for development and progression
      HFrEF. Pathologic changes in this gene signaling network are only reversed towards normal
      levels when ventricular function improves. One potential mechanism for failure to improve
      ventricular function in HFrEF patients unresponsive to beta blocker therapy is a lack of
      heart rate reduction.

      Ivabradine is an FDA-approved medication believed to have therapeutic benefit in HFrEF
      patients through reduction in heart rate independent of beta-blockade. Ivabradine has been
      shown to reduce the risk of hospitalization for worsening HF in patients with stable,
      symptomatic chronic heart failure with reduced EF (≤ 35%)in sinus rhythm with resting heart
      rate ≥ 70 bpm and who are on maximally tolerated doses of beta blockers or who have a
      contraindication to beta blockers.

      Given the high rate of mortality and hospitalization of HFrEF patients even with current
      therapies, there is a large unmet need for improving HFrEF therapy. The goals of this study
      are to test the hypothesis that heart rate reduction is an important antecedent for
      improvement in ventricular function, and to identify components of the beta1-adrenergic
      receptor gene signaling network responsible for improvement in ventricular function caused by
      heart rate reduction.
The Pulse Reduction on Beta-blocker and Ivabradine Therapy (PROBE-IT) Study is a
      double-blind, randomized, two-arm parallel group, placebo-controlled design that compares the
      effect of heart rate reduction on ventricular reverse remodeling (assessed by LVEF change at
      24 weeks) and on the beta1-gene signaling network in NYHA Class I-III HFrEF patients with an
      idiopathic dilated cardiomyopathy etiology (HFrEF/IDC), who are in sinus rhythm and whose
      heart rates remain ≥ 70 bpm on target or maximally tolerated doses of beta-blockers to which
      they have evidence of non-response by LVEF (< 5 absolute percentage points).

      Eligible patients will be randomized (2:1) to blinded treatment with ivabradine or matching
      placebo and will be initiated as per Corlanor® prescribing information over 4 weeks. The dose
      at 4 weeks post randomization will be considered the intention-to-treat end of titration
      dose, but further dose adjustment can be made based on clinical factors.

      The primary endpoint, i.e., effect of heart rate reduction on reverse remodeling (LVEF), will
      be assessed after 24 weeks. LV phenotyping by 3D-echocardiography, endomyocardial biopsy and
      coronary sinus sampling for cardiac norepinephrine levels will be performed at baseline and
      at 24 weeks. Exercise testing at baseline will be performed to assess level of beta blockade.
      Upon completion of the study, gene expression in endomyocardial biopsy tissue samples for
      each patient will be quantified using RNA-seq and quantified with respect to phenotypic
      measurements including LVEF and heart rate changes.

      After the Week 24 Visit, patients will return for an End-of-Study Visit and be offered open
      label ivabradine with dose initiation accomplished by stopping study drug and starting
      Corlanor at 5 mg BID or 2.5 mg BID if the patient is taking that dose of study drug.
      Investigators and patients will not be informed of the blinded study drug assignment at the
      time of study completion.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Basic Science
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Left ventricular reverse remodeling according to heart rate response
time frame: 24 weeks
description: Improvement in left ventricular ejection fraction (LVEF) of ≥ 5 absolute percentage points in patients above vs. below median HR reduction for all subjects.
measure: Comparison of gene expression abundances by heart rate response
time frame: 24 weeks
description: Quantification of changes in mRNA and microRNA abundance based on response above and below median for all subjects.
measure: Left ventricular reverse remodeling by treatment group (ivabradine vs. placebo)
time frame: 24 weeks
description: Comparison of change (absolute LVEF percentage points) in subjects randomized to ivabradine vs. placebo.
arm group label: Ivabradine
arm group type: Active Comparator
description: Patients will receive ivabradine 2.5-7.5 mg PO bid in addition to baseline maximum-tolerated beta-blocker therapy.
arm group label: Placebo
arm group type: Placebo Comparator
description: Patients will receive placebo bid in addition to baseline maximum-tolerated beta-blocker therapy.
intervention type: Drug
intervention name: Ivabradine
arm group label: Ivabradine
other name: Corlanor
intervention type: Drug
intervention name: Placebo
arm group label: Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Michael R Bristow, MD PhD
role: Principal Investigator
affiliation: University of Colorado, Denver
facility: 
facility: 
country: United States
citation: Kao DP, Lowes BD, Gilbert EM, Minobe W, Epperson LE, Meyer LK, Ferguson DA, Volkman AK, Zolty R, Borg CD, Quaife RA, Bristow MR. Therapeutic Molecular Phenotype of beta-Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy. Circ Cardiovasc Genet. 2015 Apr;8(2):270-83. doi: 10.1161/CIRCGENETICS.114.000767. Epub 2015 Jan 30.
PMID: 25637602
citation: Lowes BD, Zolty R, Minobe WA, Robertson AD, Leach S, Hunter L, Bristow MR. Serial gene expression profiling in the intact human heart. J Heart Lung Transplant. 2006 May;25(5):579-88. doi: 10.1016/j.healun.2006.01.006. Epub 2006 Apr 11.
PMID: 16678038
citation: Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002 May 2;346(18):1357-65. doi: 10.1056/NEJMoa012630.
PMID: 11986409
citation: Tardif JC, O'Meara E, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K; SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011 Oct;32(20):2507-15. doi: 10.1093/eurheartj/ehr311. Epub 2011 Aug 29.
PMID: 21875858
citation: Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010 Sep 11;376(9744):886-94. doi: 10.1016/S0140-6736(10)61259-7.
PMID: 20801495
citation: Bristow MR. Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011 Oct 28;109(10):1176-94. doi: 10.1161/CIRCRESAHA.111.245092.
PMID: 22034480
responsible party type: Sponsor
mesh term: Cardiomyopathies
mesh term: Cardiomyopathy, Dilated
mesh term: Heart Failure, Systolic
mesh term: Ventricular Remodeling
mesh term: Atrial Remodeling
sharing ipd: Yes
ipd description: Upon completion of primary data analysis, all gene expression data will be submitted to the Gene Expression Omnibus (GEO). In addition to the standard descriptive and protocol information, the Metadata Spreadsheet will contain subject information required to reproduce primary analyses. Once released by GEO these data will be available for public download. The investigators anticipate this to be complete approximately 2 years after the completion of final subject follow-up.